Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Araceli Biosciences has raised $7.2 million in Seed funding, bringing its total financing to $11.2 million to improve its AI-driven imaging technology for drug discovery. Meanwhile, Keymed Biosciences Inc. has received IND approval for its CDH17-targeted ADC, CM518D1, which is currently in Phase I/II trials for solid tumors in China.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
